Adebrelimab and Bevacizumab Plus Platinum Chemotherapy in Triple-Negative Breast Cancer With Brain Metastases - Summary - MDSpire
From the Journals
Clinical Guidelines

Adebrelimab and Bevacizumab Plus Platinum Chemotherapy in Triple-Negative Breast Cancer With Brain Metastases

In a Chinese phase II study (ABC) reported in the Journal of Clinical Oncology, Li et al found that the combination of the PD-L1 inhibitor adebrelimab, bevacizumab, and cisplatin or carboplatin showed...

Share

A phase II study led by Li et al. at the Fudan University Shanghai Cancer Center explored the efficacy of a combination therapy involving the PD-L1 inhibitor adebrelimab, bevacizumab, and either cisplatin or carboplatin in triplenegative breast cancer patients with brain metastases. The trial included 35 patients and reported a CNS objective response rate of 77.1%, with a median progression-free survival of 8.3 months. Adverse events were manageable with no treatment-related deaths, suggesting further investigation is warranted.

Original Source(s)

Adebrelimab and Bevacizumab Plus Platinum Chemotherapy in Triple-Negative Breast Cancer With Brain Metastases

  • by Matthew Stenger

  • April 22, 2026

Related Content

CD40 Overexpression Emerges as a Potential Biomarker for Angioimmunoblastic T-Cell Lymphoma

Researchers at The University of Texas MD Anderson Cancer Center have identified CD40 overexpression as a potential prognostic biomarker for angioimmunoblastic T-cell lymphoma, a rare subtype of non-H...

First-Line Zongertinib in Advanced <em>HER2</em>-Mutant NSCLC

In a phase IA to IB trial reported in The New England Journal of Medicine, Heymach et al found that first-line zongertinib was active in patients with advanced or metastatic HER2-mutant non–small cell...

Lung Cancer’s Hidden Layers

Study shows that tumor complexity can limit biopsy-based diagnosis

  • April 22, 2026

  • 2 min